Baidu
map

糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

Journal of Diabetes(《糖尿病期刊》)被SCIE收录

2012-10-06 MedSci MedSci原创

糖尿病
关注

2012年Journal of Diabetes《糖尿病期刊》被汤森路透的SCIE(Science Citation Index Expanded)收录，首个影响因子将于2013年6月公布。这是继2010年6月被MEDLINE收录以来，本刊所取得的又一个里程碑式的进步。 Journal of Diabetes由上海交通大学瑞金医院与国际著名期刊出版集团Wiley-Blackwell于2009年联

2012年Journal of Diabetes《糖尿病期刊》被汤森路透的SCIE(Science Citation Index Expanded)收录，首个影响因子将于2013年6月公布。这是继2010年6月被MEDLINE收录以来，本刊所取得的又一个里程碑式的进步。
Journal of Diabetes由上海交通大学瑞金医院与国际著名期刊出版集团Wiley-Blackwell于2009年联合创办，聘请上海瑞金医院宁光教授、美国 Mount Sinai医学院Zachary Bloomgarden教授担任主编。Journal of Diabetes致力于将中国糖尿病医生和研究者的最新成果介绍给国际糖尿病学界，同时及时将国际最新研究成果介绍给国内，促进糖尿病研究的进一步发展。
本刊主编和编委们愿意免费为研究人员的实验设计提供建设性的反馈意见，研究者可以在研究初期就获得来自世界知名糖尿病专家的指导，从而获得更多的成功机会。
本刊采用功能强大的在线投稿系统，快速的同行评审过程，接受的论文通过纸本与Wiley Online Library平台同步发行，以最快的速度传播给全球读者。
关于本刊详细信息及最新内容，请访问：www.jdiabetes.com
 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636579, encodeId=6f1c16365e9db, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jul 16 23:47:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5948, encodeId=caa759484a, content=收录文章到底有什么要求呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=446084655, createdName=yunxisunny, createdTime=Mon Jul 22 09:27:00 CST 2013, time=2013-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759203, encodeId=1d2d1e592033f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Nov 16 19:47:00 CST 2012, time=2012-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901012, encodeId=350b1901012b4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 29 02:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374672, encodeId=362813e46729f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 08 06:47:00 CST 2012, time=2012-10-08, status=1, ipAttribution=)]
    2013-07-16 ms9608593228839890

    #DIA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1636579, encodeId=6f1c16365e9db, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jul 16 23:47:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5948, encodeId=caa759484a, content=收录文章到底有什么要求呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=446084655, createdName=yunxisunny, createdTime=Mon Jul 22 09:27:00 CST 2013, time=2013-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759203, encodeId=1d2d1e592033f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Nov 16 19:47:00 CST 2012, time=2012-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901012, encodeId=350b1901012b4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 29 02:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374672, encodeId=362813e46729f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 08 06:47:00 CST 2012, time=2012-10-08, status=1, ipAttribution=)]
    2013-07-22 yunxisunny

    收录文章到底有什么要求呀

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1636579, encodeId=6f1c16365e9db, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jul 16 23:47:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5948, encodeId=caa759484a, content=收录文章到底有什么要求呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=446084655, createdName=yunxisunny, createdTime=Mon Jul 22 09:27:00 CST 2013, time=2013-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759203, encodeId=1d2d1e592033f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Nov 16 19:47:00 CST 2012, time=2012-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901012, encodeId=350b1901012b4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 29 02:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374672, encodeId=362813e46729f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 08 06:47:00 CST 2012, time=2012-10-08, status=1, ipAttribution=)]
    2012-11-16 ms5439512287675881

    #BET#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1636579, encodeId=6f1c16365e9db, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jul 16 23:47:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5948, encodeId=caa759484a, content=收录文章到底有什么要求呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=446084655, createdName=yunxisunny, createdTime=Mon Jul 22 09:27:00 CST 2013, time=2013-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759203, encodeId=1d2d1e592033f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Nov 16 19:47:00 CST 2012, time=2012-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901012, encodeId=350b1901012b4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 29 02:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374672, encodeId=362813e46729f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 08 06:47:00 CST 2012, time=2012-10-08, status=1, ipAttribution=)]
    2013-06-29 木头人513

    #Diabetes#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1636579, encodeId=6f1c16365e9db, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jul 16 23:47:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5948, encodeId=caa759484a, content=收录文章到底有什么要求呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=446084655, createdName=yunxisunny, createdTime=Mon Jul 22 09:27:00 CST 2013, time=2013-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759203, encodeId=1d2d1e592033f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Nov 16 19:47:00 CST 2012, time=2012-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901012, encodeId=350b1901012b4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 29 02:47:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374672, encodeId=362813e46729f, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 08 06:47:00 CST 2012, time=2012-10-08, status=1, ipAttribution=)]
    2012-10-08 jichang

    #SCIE#

    0

相关资讯

Circulation：即刻血运重建有益高危糖尿病心脏病患者（BARI 2D研究）

　　美国学者在大型BARI 2D试验中表明，在伴有广泛冠脉病变或左室功能受损的糖尿病患者中，即刻冠脉搭桥术（CABG）策略可显著降低死亡/心梗/卒中发生率。论文于2012年9月24日在线发表于《循环》（Circulation）杂志。 　　BARI 2D试验给予2型糖尿病患者即可冠脉血运重建（REV）联合强化内科治疗（MED）或单纯MED。此项研究依据患者随机化时评估指标制定血管造影风险

Diabetes Care：甘精胰岛素不增加肿瘤风险（法国研究）

　　一项基于法国国家管理数据库的队列研究表明，在新开始基础胰岛素治疗的较大患者队列中，与使用其他基础胰岛素的患者相比，接受甘精胰岛素治疗的患者未发现恶性肿瘤风险增加。然而，由于随访时间不超过4年，进一步更长期的研究尤为必要。研究在2012年9月10日在线发表于《糖尿病护理》（Diabetes Care）杂志。　　该研究旨在探讨与其他基础胰岛素相比，甘精胰岛素的使用与2型糖尿病患者的总体和

CCQO：极端气温升高心血管死亡风险

　　澳大利亚学者的一项研究表明，热浪和寒潮期间的极端气温可升高心血管疾病早亡风险。论文在线发表于《循环：心血管质量与结果》（Circ Cardiovasc Qual Outcomes）杂志。 　　暴露于极端气温可诱发血压、血液粘稠度、胆固醇和心率变化。随着肥胖和糖尿病等相关疾病发病率升高，易受极端气温影响的人群亦不断增多，并且可升高未来疾病负担。此项研究采集了澳大利

NEJM评论：II型糖尿病的预防障碍在哪里

 美国糖尿病预防项目(Diabetes Prevention Program,DPP) 临床试验及其10年转归研究(DPPOS)均得到美国国立卫生研究院(NIH)资助，研究结果显示，某些特定的干预措施可以预防或显著地阻止2型糖尿病的发生，安全性和效价比均很可观。然而，糖尿病预防措施并没有在美国得到推广，人力和财力成本惊人并呈不断增长的态势。因此有必要明确是什么原因阻止了DPP糖尿病预防干

Lancet Oncology：儿童胰腺接受高剂量辐射或导致糖尿病风险增加

    欧洲的研究人员发现，儿童胰腺接受辐射可导致在几十年后发展为糖尿病的风险增加，特别是当暴露于高剂量辐射时。     根据法国古斯塔夫研究所 Florent de Vathaire博士和他的同事的研究，当胰腺的辐射剂量为1戈瑞时，估计以后发展为糖尿病的相对风险为1.61（95%可信区间1.21至2.68）。而根据研究人员报告在Lan

联合国再开NCD高级别会议

　　2012年9月19日，联合国再次举行了非传染性疾病（NCD）高级别会议。出席会议的包括美国癌症协会（ACS）主席约翰·塞弗林，美国糖尿病协会（ADA）主席拉里·豪斯纳和美国心脏协会主席（AHA）南希·布朗。会议有助于提升非传染性疾病的重要性，并将慢性非传染性疾病（包括恶性肿瘤、糖尿病、心血管疾病，慢性呼吸系统疾病）提上全球健康议程。会议达成联合国一致通过的“关于预防和控制非传染性疾病问题高级别

Baidu
map
Baidu
map
Baidu
map